Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic data of patients with osteoarthritis and those with rheumatoid arthritis

From: Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis

  Osteoarthritis
(n= 11)
Rheumatoid arthritis
(n= 18)
Age in years, mean ± SD 67.20 ± 7.35 57.17 ± 9.51
Females/Males 10:1 17:1
Duration of disease in months, mean ± SD 79.64 ± 62.66 114.85 ± 49.54
Treatment, number (percentage)   
   Prednisolone   15 (83%)
   DMARDs   18 (100%)
   Methotrexate   16 (89%)
   Sulfasalazine   2 (11%)
   Hydroxychloroguine   7 (39%)
   Leflunomide   5 (28%)
   Azathioprine   3 (17%)
  1. DMARD, disease-modifying antirheumatic drug; SD, standard deviation.